Annals of the American Thoracic Society · 2026
Epidemiology of Alpha-1 Antitrypsin Deficiency in the Veterans Health Administration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riley Leonard, Fredenrich Robert, Bearce Matthew, Govindan Sushant, Schafer Spencer, Campos Michael, Lascano Jorge
Аннотация
RATIONALE: AAT (alpha-1 antitrypsin) deficiency (AATD) is a known but underrecognized genetic cause of chronic obstructive pulmonary disease (COPD) and liver disease. Little is known about the epidemiology and burden of AATD among U.S. veterans.
OBJECTIVES: To examine the veteran characteristics and epidemiology of AATD and severe AATD throughout the Veterans Health Administration.
METHODS: Data were obtained from the electronic health record to describe demographic, clinical, testing outcomes, and geographic data for veterans between January 1, 2010, and December 31, 2019. Multivariable logistic regression analysis was performed to evaluate veteran characteristics associated with AATD. We defined intermediate AATD as a serum AAT concentration >57 and <100 mg/dl or any allelic combination other than PI*MM, PI*MS, PI*SZ, and PI*ZZ. Severe AATD was defined by PI*ZZ and PI*SZ genotypes as well as any combination with a serum AAT concentration ≤57 mg/dl (≤11 μmol/L).
RESULTS: Among 12 million veterans enrolled during the study period, 175,508 were tested for AATD; 8,832 received diagnoses of intermediate AATD and 3,088 of severe AATD. The positivity rate of AATD varied year to year, ranging from 62 to 76 cases per 1,000 persons tested. AATD occurred in 57 cases per 1,000 persons tested with COPD, and there were 66 cases of AATD per 1,000 persons tested with liver disease; however, testing rates of COPD (4.04%) or liver disease (17.91%) were low. There was a heterogeneous distribution of AATD throughout the United States. Factors associated with detection and diagnosis of AATD included younger age, White race, and no history of tobacco use.
CONCLUSIONS: This study represents a national analysis of AATD in the Veterans Health Administration. Although the annual positivity rates of AATD among those tested varied over the decade, it confirmed AATD is prevalent in veterans. However, the number of eligible veterans tested is low, which highlights the need for increased awareness of this condition.
OBJECTIVES: To examine the veteran characteristics and epidemiology of AATD and severe AATD throughout the Veterans Health Administration.
METHODS: Data were obtained from the electronic health record to describe demographic, clinical, testing outcomes, and geographic data for veterans between January 1, 2010, and December 31, 2019. Multivariable logistic regression analysis was performed to evaluate veteran characteristics associated with AATD. We defined intermediate AATD as a serum AAT concentration >57 and <100 mg/dl or any allelic combination other than PI*MM, PI*MS, PI*SZ, and PI*ZZ. Severe AATD was defined by PI*ZZ and PI*SZ genotypes as well as any combination with a serum AAT concentration ≤57 mg/dl (≤11 μmol/L).
RESULTS: Among 12 million veterans enrolled during the study period, 175,508 were tested for AATD; 8,832 received diagnoses of intermediate AATD and 3,088 of severe AATD. The positivity rate of AATD varied year to year, ranging from 62 to 76 cases per 1,000 persons tested. AATD occurred in 57 cases per 1,000 persons tested with COPD, and there were 66 cases of AATD per 1,000 persons tested with liver disease; however, testing rates of COPD (4.04%) or liver disease (17.91%) were low. There was a heterogeneous distribution of AATD throughout the United States. Factors associated with detection and diagnosis of AATD included younger age, White race, and no history of tobacco use.
CONCLUSIONS: This study represents a national analysis of AATD in the Veterans Health Administration. Although the annual positivity rates of AATD among those tested varied over the decade, it confirmed AATD is prevalent in veterans. However, the number of eligible veterans tested is low, which highlights the need for increased awareness of this condition.